SLGL News and Press, Sol-Gel Technologies Ltd. From 11/20/25

2025-11-20 07:49:50 ET More on Sol-Gel Technologies Sol-Gel announces Health Canada approval of EPSOLAY Seeking Alpha’s Quant Rating on Sol-Gel Technologies Historical earnings data for Sol-Gel Technologies Financial information for Sol-Gel Technologie...

Sol-Gel intends to pursue high-frequency BCC as an additional indication for its lead drug candidate SGT-610, which, if approved, could at least double the drug’s commercial potential In September 2025, Sol-Gel announced Health Canada approval of EPSOLAY Sol-Gel signed an additiona...

2025-09-04 07:51:07 ET More on Sol-Gel Technologies Financial information for Sol-Gel Technologies Read the full article on Seeking Alpha For further details see: Sol-Gel announces Health Canada approval of EPSOLAY

NESS ZIONA, Israel, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, a Phase-1b, double b...

2025-08-15 08:57:15 ET More on Sol-Gel Technologies Financial information for Sol-Gel Technologies Read the full article on Seeking Alpha For further details see: Sol-Gel Technologies GAAP EPS of -$1.57, revenue of $5.89M

BRT Apartments Corp. (MD) (BRT) is expected to report $0.36 for Q2 2025 Genprex Inc. (GNPX) is expected to report for Q2 2025 Diguang International Development Company Ltd (DGNG) is expected to report for Q2 2025 Interpace Biosciences Inc. (IDXG) is expected to report for Q2 2025 ...

Patient enrollment for our ongoing Phase-3 clinical trial of SGT-610 for Gorlin Syndrome has been completed; top-line results are expected in the fourth quarter of 2026 Phase-1b proof-of-concept clinical trial of SGT-210 for Darier disease is ongoing Sol-Gel and Mayne Pharma Announce the ...

Sol-Gel Technologies Ltd. (SLGL) is expected to report for Q2 2025

2025-08-14 18:45:05 ET Sol-Gel Technologies Ltd. (SLGL) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 5.09%. The average open to low on the day of earnings was -3.95%. The average open...

2025-05-23 10:28:31 ET More on Sol-Gel Technologies Financial information for Sol-Gel Technologies Read the full article on Seeking Alpha For further details see: Sol-Gel Technologies reports Q1 results